Publications

Sabnis N, Raut S, Nagarajan B, Kapic A, Dossou A, Lothstein L, Fudala R, Bunnell B, Lacko AG. Evaluation of a spontaneously assembling lipo-peptide nano-complex, transporting the anthracycline drug AD198, for personalized therapy of Ewing Sarcoma (EWS). Bioconjugate Chemistry, 2023, In Press.

Lothstein L, Soberman J, Parke D, Gandhi J, Sweatman T, Seagroves T. Pivarubicin is more effective than doxorubicin against triple-negative breast cancer in vivo. Oncology Res. 2020;28(5):451-465.

Pandey S, Bourn J, Cekanova M. Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. Oncotarget. 2018; 9:28514-31. PMID: 29983877. (PubMed) (PDF)

Mittal NK, Mandal B, Balabathula P, Setua S, Janagam DR, Lothstein L, Thoma LA, Wood GC. Formulation, development, and in vitro evaluation of a CD22-targeted liposomal system containing a non-cardiotoxic anthracycline for B-cell malignancies. Pharmaceutics. 2018; 10. pii: E50. PMID: 29662041. (PubMed) (PDF)

Edwards SK, Han Y, Liu Y, Kreider BZ, Liu Y, Grewal S, Desai A, Baron J, Moore CR, Luo C, Xie P. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells. Leuk Res. 2016; 41:85-95. PMID: 26740054. (PubMed) (PDF)

Smolensky D, Rathore K, Cekanova M. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD 198 chemotherapy in human bladder cancer cells in vitro. BMC Cancer. 2015; 15:927. PMID: 26597249. (PubMed) (PDF)

Rathore K, Cekanova M. A novel derivative of doxorubicin, AD 198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro. Drug Des Devel Ther. 2015; 9:5323-35. PMID: 26451087. (PubMed) (PDF)

Moore CR, Edwards SK, Xie P. Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms. J Cancer
Sci Ther. 2015 7:67-74. PMID: 25960828. (PubMed) (PDF)

Mittal NK, Bhattacharjee H, Mandal B, Balabathula P, Thoma LA, Wood GC. Targeted liposomal drug delivery systems for the treatment of B cell malignancies. J Drug Target. 2014; 22:372-86. PMID: 24433007. (PubMed) (PDF)

Edwards SK, Moore CR, Liu Y, Grewal S, Covey LR, Xie P. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma. BMC Cancer. 2013; 13:481. PMID: 24131623. (PubMed)

Díaz Bessone MI, Berardi DE, Campodónico PB, Todaro LB, Lothstein L, Bal de Kier Joffé ED, Urtreger AJ. Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs. Breast Cancer Res Treat. 2011; 126:577-87. PMID: 20512658 (PubMed)

Cai C, Lothstein L, Morrison RR, Hofmann PA. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). J Pharmacol Exp Ther. 2010; 335:223-30. PMID: 20668052. (PubMed) (PDF)

Du Z, Fan M, Kim JG, Eckerle D, Lothstein L, Wei L, Pfeffer LM. An interferon-resistant Daudi cell line with a STAT2 defect is resistant to apoptosis induced by chemotherapeutic agents. J Biol Chem. 2009; 284:27808-15. PMID: 19687011 (PubMed) (PDF)

Hofmann PA, Israel M, Koseki Y, Laskin J, Gray J, Janik A, Sweatman TW, Lothstein L. N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation. J Pharmacol Exp Ther. 2007; 323:658-64. PMID:17693586. (PubMed)

He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L, Epand RF, Epand RM, Lee RM. Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem. 2007; 101:1210-21. PMID: 17226776. (PubMed)

Lothstein L, Savranskaya L, Sweatman TW. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicity circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity. Leuk Res. 2007; 31:1085-95. PMID: 17187856. (PubMed)

Lothstein L, Savranskaya L, Barrett CM, Israel M, Sweatman TW. N-Benzyladriamycin-14-valerate (AD 198) activates protein kinase C-delta holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx. Anticancer Drugs. 2006; 17:495-502. PMID: 16702805. (PubMed)

He Y, Liu J, Durrant D, Yang HS, Sweatman T, Lothstein L, Lee RM. N-benzyladriamycin-14-valerate (AD 198) induces apoptosis through protein kinase C-delta-induced phosphorylation of phospholipid scramblase 3. Cancer Res. 2005; 65:10016-23. PMID: 16267027. (PubMed) (PDF)

Bilyeu JD, Panta GR, Cavin LG, Barrett CM, Turner EJ, Sweatman TW, Israel M, Lothstein L, Arsura M. Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines. Mol Pharmacol. 2004; 65:1038-47. PMID: 15044634. (PubMed) (PDF)

Panta GR, Kaur S, Cavin LG, Cortés ML, Mercurio F, Lothstein L, Sweatman TW, Israel M, Arsura M. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol. 2004; 24:1823-35. PMID: 14966265 (PubMed) (PDF)

Roaten JB, Kazanietz MG, Caloca MJ, Bertics PJ, Lothstein L, Parrill AL, Israel M, Sweatman TW. Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity. Mol Cancer Ther. 2002; 1:483-92. PMID: 12479266. (PubMed) (PDF)

Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, Lothstein L. Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002; 1:469-81. PMID: 12479265. (PubMed) (PDF)

Roaten JB, Kazanietz MG, Sweatman TW, Lothstein L, Israel M, Parrill AL. Molecular models of N benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta. J Med Chem. 2001; 44:1028-34. PMID: 11297449. (PubMed)

Lothstein L, Israel M, Sweatman TW. Anthracycline drug targeting: cytoplasmic versus nuclear–a fork in the road. Drug Resist Updat. 2001; 4:169-77. Review. PMID: 11768330 (PubMed)

Sweatman TW, Seshadri R, Israel M. Pharmacology of N-benzyladriamycin-14-valerate in the rat. Cancer Chemother Pharmacol. 1999; 43:419-26. PMID: 10100599. (PubMed)

Lothstein L, Suttle DP, Roaten JB, Koseki Y, Israel M, Sweatman TW. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Biochem Pharmacol. 2000; 60:1621-8. PMID: 11077044 (PubMed)

Pawlik CA, Israel M, Sweatman TW, Lothstein L. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities. Oncol Res. 1998; 10:209-17. PMID: 9778692 (PubMed)

Glaves D, Murray MK, Raghavan D. Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: analysis in a preclinical survival model. Clin Cancer Res. 1996; 2:1315-9. PMID: 9816302 (PubMed)

Publications

Headquarters

About

Pipeline

Contact Us